Oxford Biomedica PLC Publication in the Journal Nature Communications (6118A)
March 27 2017 - 5:45AM
UK Regulatory
TIDMOXB
RNS Number : 6118A
Oxford Biomedica PLC
27 March 2017
Oxford BioMedica Announces Publication in the Journal Nature
Communications on Study Results Supporting the Transgene Repression
in vector Production (TRiP) system
Data demonstrates benefits of the Group's proprietary "TRiP"
system in enhancing production yields for a broad range of gene
therapy vectors
Oxford, UK - 27 March 2017: Oxford BioMedica plc (LSE:OXB)
("Oxford BioMedica" or "the Group"), a leading gene and cell
therapy group, today announces the publication of study results in
the journal Nature Communications supporting the Group's Transgene
Repression in vector Production (TRiP) system.
This new vector production approach addresses a common problem
of reduced yield during the manufacture of gene therapy vectors
when the therapeutic gene is expressed highly in production cells.
The TRiP system suppresses this undesirable expression without
compromising expression of the therapeutic protein in target cells.
The findings published in the peer-reviewed article demonstrate
significant gains in the production yields of a broad range of gene
therapy vectors, including those based on lentivirus, adenovirus
and AAV. We believe that the improved yield facilitated by the TRiP
system will allow significant reduction in production cost of the
viral vector needed for a patient dose and also unlock the
development for gene therapies that are currently made impractical
due to this common problem.
The publication in Nature Communications is entitled: "Enhancing
titres of therapeutic viral vectors using the Transgene Repression
in Vector Production (TRiP) system" DOI: 10.1038/NCOMMS14834.
The TRiP system is subject to patent applications derived from
WO 2015/092440, which will expire in December 2034.
Commenting on the publication, John Dawson, Chief Executive
Officer of Oxford BioMedica, said: "The data published demonstrates
Oxford BioMedica's innovative capabilities and our commitment to
invest in our technology to maintain our leading position in vector
manufacture for gene therapy products. As demand for vectors grows
with the introduction of gene and cell therapy products, we are
confident there will be significant demand from third parties to
licence the rights to utilise our TRiP technology."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Jefferies (Corporate Broker): Tel: +44 (0)20 7029 8000
Gil Bar-Nahum
Simon Hardy
Lee Morton
Max Jones
Nicholas Moore
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 250 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUGCWUPMUBM
(END) Dow Jones Newswires
March 27, 2017 05:45 ET (09:45 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024